Petersilia, J. (1998). Probation and parole. In M. Tonry (Ed.), The handbook of crime and punishment (p. 563). New York: Oxford University Press.

Petersilia, J. (1999). Parole and prisoner re-entry in the United States. In M. Tonry and J. Petersilia (Eds.), Prisons: Crime and justice (p. 502). Chicago: University of Chicago Press.

Rain, S.D., Williams, V.F., Robbins, P.C., Manahan, J., and Steadman, H.J. (2003). Perceived coercion at hospital admission and adherence to mental health treatment after discharge. Psychiatric Services, 54(1), 103-105.

Ridgely, M.S., Borum, R., and Petrila, J. (2001). Effectiveness of involuntary outpatient treatment: Empirical evidence and the experience of eight states. (MR-1340-CSCR). Santa Monica, CA: RAND Corporation.

Riley, K.J., Ebener, P.A., Chiesa, J.R., Turner, S., and Ringel, J.S. (2000). Drug offenders and the criminal justice system: Will Proposition 36 treat or create problems? (IP-204). Santa Monica, CA: RAND Corporation.

Siegel, D.M., Grudzinskas, A.J., Jr., and Pinals, D.A. (2001). Old law meets new medicine: Revisiting existing involuntary psychotropic medication of the criminal defendant. Wisconsin Law Review, 307, 313.

Winick, J. (1997). Symposium on coercion: An interdisciplinary examination of coercion, exploitation, and the law: III. Coerced confinement and treatment. Denver Univiversity Law Review, 74, 1145.

Front Matter (R1-R14)

Executive Summary (1-6)

1 Introduction and Background (7-15)

2 Clinical Trials (16-22)

3 Treatment, Financing, and Costs (23-36)

4 Behavioral Responses and Consent (37-53)

References (54-60)

Appendix A: Vaccines and Depot Medications for Drug Addiction: Rationale, Mechanisms of Action, and Treatment Implications (61-97)

Appendix B: What Will We Learn from the FDA Clinical Trials Process and What Will We Still Want to Know About Immunotherapies and Depot Medications to Treat Drug Dependence? (98-124)

Appendix C: Putting Addiction Treatment Medications to Use: Lessons Learned (125-139)

Appendix D: Adoption of Drug Abuse Treatment Technology in Speciality and Primary Care Settings (140-172)

Appendix E: The Use of Immunotherapies and Sustained-Release Formulations in the Treatment of Drug Addiction: Will Current Law Support Coercion? (173-187)

Appendix F: Ethical Issues in Immunotherapies and Depot Mechanisms for Substance Abuse (188-212)

Appendix G: Costs and Benefits of Immunotherapies or Depot Medications for the Treatment of Drug Abuse (213-240)

Appendix H: Anticipating Unintended Consequences of Vaccine-Like Immunotherapies for Addictive Drug Use (241-275)

Appendix I: Vaccines and Immunotherapies to Control Addiction in Minors: The Legal Framework (276-299)

Appendix J: Biographical Sketches of Committee Members and Staff (300-306)